# Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age

> **NCT07071558** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 240 (actual)

## Conditions studied

- Respiratory Syncytial Virus Immunization

## Interventions

- **BIOLOGICAL:** RSV vaccine formulation 1 dose
- **BIOLOGICAL:** RSV vaccine formulation 2 dose
- **BIOLOGICAL:** RSV vaccine formulation 3 dose
- **BIOLOGICAL:** RSV vaccine formulation 4 dose
- **BIOLOGICAL:** RSV vaccine formulation 5 dose
- **BIOLOGICAL:** RSV vaccine formulation 6 dose
- **BIOLOGICAL:** RSV vaccine formulation 7 dose
- **BIOLOGICAL:** RSV vaccine formulation 8 dose

## Key facts

- **NCT ID:** NCT07071558
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-14
- **Primary completion:** 2026-03-17
- **Final completion:** 2026-03-17
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07071558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07071558, "Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07071558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*